2024 Annual Report

DAILIES AquaComfort PLUS, our most affordable daily disposable contact lens in monofocal, astigmatism-correcting and

multifocal options, delivers dependable performance by working with tears to release moisture with every blink. This lens

is designed for value-conscious wearers who want the flexibility and simplicity of a daily disposable lens.

Air Optix, our more affordable monthly replacement product line, features SiHy contact lenses in monofocal, astigmatism-

correcting and multifocal options, as well as Air Optix Colors and Air Optix plus HydraGlyde contact lenses. Air Optix plus

HydraGlyde brings together two innovative technologies—SmartShield technology and HydraGlyde moisture matrix—for a

unique combination of deposit protection and longer-lasting lens surface moisture.

We continue to experience market growth driven by trade-up to premium lenses, expansion of toric and multifocal

specialty lenses, as well as increasing penetration in emerging markets.

Our key brands in our ocular health portfolio include the Systane family of artificial tear and related dry eye products,

Pataday family of eye allergy products, as well as the Opti-Free and Clear Care lines of multi-purpose and hydrogen

peroxide disinfecting solutions, respectively.

Alcon currently holds a market leading position in artificial tears. We continue to focus on core product performance while

increasing promotion behind a best-in-class innovation portfolio under the brand leadership of Systane artificial tears. The

Systane portfolio is a comprehensive offering of ocular health solutions, most of which are indicated for the temporary

relief of burning and irritation due to dryness of the eye. The Systane portfolio includes products for daily and nighttime

relief, as well as products for discomfort associated with contact lens wear. In 2021, we continued significant international

expansion for Systane Ultra multi-dose preservative-free ("MDPF") and Systane Hydration MDPF. In 2022, we launched a

preservative-free formulation of Systane Complete. By adding the option of MDPF presentations to our portfolio, we

address a key need by many eye care practitioners for effective dry eye relief without preservatives. In 2025, we plan to

extend our Systane line with a new formulation that combines the strength of Systane Complete nano-lipids with hyaluronic

acid called Systane Pro to provide relief from more severe dry eye symptoms. Systane Pro will be the first Systane

lubricating drop with HA and lipids for all types of dry eye relief.

Previously available only by prescription, in 2020, we began to offer the Pataday family of allergy relief eye drops over-the-

counter in the US. Pataday Twice Daily Relief, Pataday Once Daily Relief and Pataday Once Daily Extra Strength eye drops

each contains olopatadine, the number one doctor-prescribed active ingredient for eye allergy relief.

In 2021, we began our expansion into the ophthalmic pharmaceutical space by acquiring the exclusive US

commercialization rights to Simbrinza, a fixed combination of a carbonic anhydrase inhibitor and an alpha-2 adrenergic

receptor agonist indicated for the reduction of elevated intraocular pressure ("IOP") in patients with open-angle glaucoma

or ocular hypertension. We then acquired Eysuvis, a corticosteroid indicated for the short-term (up to two weeks)

treatment of the signs and symptoms of dry eye disease, and Inveltys, a corticosteroid indicated for the treatment of post-

operative inflammation and pain following ocular surgery, from Kala Pharmaceuticals, Inc. in July 2022. In November 2022,

to complement our previous acquisitions, we acquired Aerie Pharmaceuticals, Inc. The Aerie transaction adds on-market

products Rhopressa, a once-daily eye drop that contains netarsudil, a Rho kinase (ROCK) inhibitor specifically designed to

target a diseased trabecular meshwork believed to be the main cause of elevated IOP in open-angle glaucoma and ocular

hypertension, and Rocklatan, a once-daily eye drop that is a fixed-dose combination of latanoprost, a prostaglandin analog

(PGA), and netarsudil, as well as a pipeline of products, including AR-15512, a Phase 3 product candidate for dry eye

disease, and R&D capabilities to expand our ophthalmic pharmaceutical presence. We are planning to launch AR-15512 in

2025, pending FDA approvals and other required registrations.

Alcon is also a market leader in contact lens care in both multi-purpose (Opti-Free PureMoist) and hydrogen peroxide

solutions (Clear Care and AOSEPT PLUS). The vast majority of our contact lens care products are comprised of disinfecting

solutions to remove harmful micro-organisms on contact lenses, with a smaller amount of sales coming from contact lens

rewetting drops to improve wearing comfort for contact lenses. We benefit from strong synergies between our contact

lens business and our contact lens care products.

Finally, our ocular health portfolio also includes artificial tear and related dry eye products marketed under the Tears

Naturale and Genteal brands, products for the temporary relief of ocular itching due to ocular allergies marketed under the

Index

Pages

Search